Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Bio Essence (BIOE) Asset Writedowns and Impairment (2021)

Bio Essence has reported Asset Writedowns and Impairment over the past 1 years, most recently at $8235.0 for Q4 2021.

For Q4 2021, Asset Writedowns and Impairment changed N/A year-over-year to $8235.0; the TTM value through Dec 2024 reached $8235.0, changed N/A, while the annual FY2024 figure was $1.1 million, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2021 was $8235.0 at Bio Essence, up from $380.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $8235.0 in Q4 2021 and troughed at $380.0 in Q1 2021.